Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin

Integumen plc (AIM: SKIN) is pleased to announce a greater than 99% reduction of bacterial growth in preliminary results of four formulations, all of which include Cannabinoid (CBD) oils, on Labskin in a range of cosmetic and skin-care treatments.

STOER For Men with CBD’s kills 99% of antibiotic-resistant bacteria

Tests, which include formulations of STOER For Men, the skin care product range owned by Integumen, were carried out on bacteria common to human skin. The bacteria tested are known to be one of the leading causes of foreign body infections with resistance to some antibiotics. While these are preliminary tests, with further results to follow, it provides clear evidence that the addition of CBD to cosmetics and skin-care treatments can play a major role in lowering the incidence of skin diseases.

Update on announcement of 7th January 2019

The Company trading update of 7 January 2019 noted that Cellulac (9.35% owned by Integumen) had developed a low-cost hemp-derived CBD oil extraction process and was collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics.

CBD Market Size

Explosive growth in the hemp-derived CBD category that has grown from a market category that did not exist five years ago to $190 Million in sales in 2017, poised to have reached $1.0 Billion in 2018, is led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $1.9B market by 2022.

Gerard Brandon (CEO of Integumen plc) commented:

I am delighted that collaboration processes, put in place by new management in H2 2018, have resulted in achieving such a great outcome in a very short period of time. This shows the extent and value of the technology and clinical expertise that exists within Integumen.

 

This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema.


As well as having an extension to the range of STOER For Men skin care products, Labskin will be offering the same test services to clients adding CBD to their skin-care and cosmetic range of products”

Labskin 

Laboratory grown human skin testing services. Specifically developed to host harmful bacteria on simulated human skin. It is the best testing platform for antimicrobial products, such as anti-dandruff shampoos and anti-acne creams, anti-aging, anti-fungal, UV sun exposure, toxic shock, and drug delivery through the skin, which cannot currently be carried out in vivo (animal models) due to ethical constraints of testing harmful bacteria.

 

TSpro disposal removes £1.19m liabilities

Divestment of TSPro GmbH to remove c€1.34m (£1.19m) of short and long term liabilities from Integumen Today the Company announces the divestment (“Disposal”) of TSpro GmbH (“TSPro”), a wholly-owned subsidiary of Integumen plc. The Company has entered into a...

Trading Update November 2018

Major Restructuring Causing Increased Growth Trading Update  The Company is pleased to announce the increased growth in product sales and contract test services at Labskin (Innovenn Limited, a wholly-owned subsidiary of Integumen plc).  With improved visibility ahead,...

Trading Update August 2018

Chairman's Statement Introduction Since Integumen’s  admission to trading on AIM in April 2017, the integration of multiple isolated and diverse business units covering oral-care, cosmetics, wound care and supported by an animal-free laboratory grown human skin...

Interim Results 2018

  Interim Report 2018 Integumen (LSE: SKIN), the non-animal-testing, skin care and cosmetic businesses developing and commercialising technologies and products for consumer use today announces its interim results for the 6 months ended 30 June 2018. Performance...